| Objective:To investigate the value of two18F-FDG PET/CT scans performed in the interim phase of chemotherapy in the evaluation of chemotherapy effect and predicting the progression-free survival on Hodgkin’s disease and aggressive non-Hodgkin’s lymphoma.Methods:18F-FDG PET/CT was performed in the same 68 patient with lymphoma after the 2-3cycles and 5-7 cycles of chemotherapy respectively. According to the 2014 NCCN guidelines, the PET/CT results of the evaluation of chemotherapy effect were divided into negative and positive respectively. All the patients were followed up for a median of 20months(5-53 month) to compare the PET/CT results with the PFS and the PFS rate.Results:The positive rate of PET/CT imaging performed in the two phases of chemotherapy showed no significant difference(29.4% vs 25.0%, P>0.05). The PFS and PFS rate showed significant differences in patients with negative and positive findings in the 2-3 cycles of chemotherapy(21 vs 14 months, P=0.007; 81.3% vs 45.0%,P=0.003) and 6-8 cycles of chemotherapy(21 vs 13 months, P=0.000; 88.2% vs 11.8%, P=0.000). There were significant differences between the positive patients(14 vs 13 months, P=0.023; 45.0% vs11.8%, P=0.028) in the two PET/CT scans,while no significant differences were showedbetween the negative patients(21 vs 21 months, P=0.727; 81.3% vs 88.2%, P=0.333).Conclusion:18F-FDG PET/CT performed after 5-7 cycles of chemotherapy could identity the false positive and false negative cases accurately, and a relatively higher value for the evaluation of prognosis was observed in the positive patients performed in the later phase of chemotherapy. So the 18F-FDG PET/CT scanning performed in the later phase of chemotherapy may be well correlated with the 1 year progression-free survival of lymphoma patients, and the secondary 18F-FDG PET/CT scanning performed to evaluate chemotherapy effect of lymphoma have important clinical value. |
PDF Full Text Request